DBV Technologies has filed for FDA approval of its VIASKIN peanut-allergy patch for children ages 4 to 7 and requested Priority Review. The application is supported by a successful Phase 3 trial involving 654 children; the patch delivers small amounts of peanut protein through the skin to gradually desensitize patients.

Business· 4d

Facts from Wikidata (CC0). Image by dbv tech via Wikimedia Commons (CC BY-SA 3.0).

DBV Technologies

empresa biofarmacéutica francesa de propiedad pública con sede en Bagneux, Francia

0miembros1here now

Pregunta a Genius Sitio

Sitio Diario

Feed Debates Acerca de

Sort by

Content type

Últimas noticias y debate sobre DBV Technologies

Sort by

Content type

DBV Technologies· Business · 10 sources · 4dStory

DBV Submits FDA Application for Peanut Allergy Patch in Young Children

Business· 4d

Facts from Wikidata (CC0). Image by dbv tech via Wikimedia Commons (CC BY-SA 3.0).

DBV Technologies across IJR

Ask Genius by OpenServe about DBV Technologies Create in Studio Build a game Watch videos

About DBV Technologies

DBV Technologies SA es una empresa biofarmacéutica francesa de propiedad pública con sede en Bagneux, Francia. DBV Technologies es conocida por desarrollar la tecnología "Viaskin" para administrar alérgenos o antígenos a la piel intacta evitando cualquier transferencia a la sangre. El desarrollo clínico de Viaskin Peanut ha recibido la designación Fast Track de la Administración de Alimentos y Medicamentos de EE. UU.

members

here now

Country: France
Headquarters: Bagneux
Inception: March 29, 2002, 2002
Website: http://www.dbv-technologies.com/

Coverage spread L0 / C100 / R0

Everything about DBV Technologies →

Related journals

Connected

France

Live room · 1 here

Be the first in the room — members see you arrive.

Join the room

Related journals

Connected

France

DBV Technologies across IJR

Ask Genius by OpenServe about DBV Technologies Create in Studio Build a game Watch videos